Charles Russell Speechlys has advised longstanding client Emergex Vaccines Holding Limited on their recent $11m equity fundraising to advance its vaccine development programme for infectious diseases.
Emergex is a UK-based biotechnology company and pioneers of developing synthetic ‘set point’ vaccines against health threats such as COVID-19, Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.
This was a follow-on round with new and existing investors after Emergex raised over $11m earlier this year in a Series A round led by a Singaporean venture capital investor, which we also advised on. Alongside this transaction, we continue to advise on Emergex’s UK and international research and development collaborations and ventures (including a Brazilian collaboration and the launch of its US subsidiary by acquisition of a US research lab).
Storme Moore-Thornicroft, co-founder and COO of Emergex, commented: “This funding round demonstrates our investors’ continuing confidence in Emergex’s unique technology in creating safe, effective vaccines that can be rapidly developed and deployed against a range of infectious diseases. Many thanks to Will and the Charles Russell Speechlys team for their instrumental advice, both from a transactional and advisory perspective.”
Will Nash commented: “We are delighted to have supported Emergex through their recent fundraising rounds which will facilitate their exciting and innovative work on deploying new technologies to develop vaccines against some of the world’s most immediate heath threats.”